NASDAQ:RVNC - Revance Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.04 -0.16 (-0.83 %)
(As of 12/19/2018 01:06 AM ET)
Previous Close$19.20
Today's Range$18.85 - $19.36
52-Week Range$18.85 - $37.45
Volume434,800 shs
Average Volume297,490 shs
Market Capitalization$736.42 million
P/E Ratio-4.75
Dividend YieldN/A
Beta1.33
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
Previous Symbol
CUSIPN/A
Phone510-742-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio6.79
Quick Ratio6.79

Price-To-Earnings

Trailing P/E Ratio-4.75
Forward P/E Ratio-5.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales2,708.81
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.51 per share
Price / Book2.54

Profitability

EPS (Most Recent Fiscal Year)($4.01)
Net Income$-120,580,000.00
Net Margins-4,205.52%
Return on Equity-61.45%
Return on Assets-51.41%

Miscellaneous

Employees134
Outstanding Shares36,990,000
Market Cap$736.42 million
OptionableOptionable

Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.04. The biopharmaceutical company earned $2.36 million during the quarter, compared to analyst estimates of $0.49 million. Revance Therapeutics had a negative return on equity of 61.45% and a negative net margin of 4,205.52%. View Revance Therapeutics' Earnings History.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Revance Therapeutics.

What price target have analysts set for RVNC?

10 Wall Street analysts have issued twelve-month target prices for Revance Therapeutics' stock. Their forecasts range from $40.00 to $60.00. On average, they expect Revance Therapeutics' stock price to reach $48.00 in the next year. This suggests a possible upside of 152.1% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

What is the consensus analysts' recommendation for Revance Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:
  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (11/7/2018)
  • 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month price target of $50 on shares of RVNC. We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive the stock higher. RVNC’s long-duration, next-generation injectable neuromodulator may be a pipeline in a product. RT002 targets a $3B+ market opportunity for both medical and aesthetic indications." (11/1/2018)

Has Revance Therapeutics been receiving favorable news coverage?

News coverage about RVNC stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Revance Therapeutics earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.

Who are some of Revance Therapeutics' key competitors?

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:
  • Mr. L. Daniel Browne, Co-Founder, CEO, Pres & Director (Age 56)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 55)
  • Mr. Cyril Allouche, Chief Accounting Officer & Corp. Controller (Age 46)
  • Mr. Tobin C. Schilke, Chief Financial Officer (Age 43)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (9.86%), BlackRock Inc. (8.64%), Franklin Resources Inc. (6.89%), Bank of New York Mellon Corp (6.66%), Alliancebernstein L.P. (4.47%) and Vanguard Group Inc. (4.07%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail, Mark J Foley and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

Which institutional investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Capital World Investors, Franklin Resources Inc., Renaissance Technologies LLC, TIAA CREF Investment Management LLC, Morgan Stanley, JPMorgan Chase & Co. and Credit Suisse AG. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Insider Buying and Selling for Revance Therapeutics.

Which institutional investors are buying Revance Therapeutics stock?

RVNC stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alliancebernstein L.P., Capital International Investors, BlackRock Inc., FMR LLC, Dimensional Fund Advisors LP, Sio Capital Management LLC and Vanguard Group Inc. View Insider Buying and Selling for Revance Therapeutics.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $19.04.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $736.42 million and generates $260,000.00 in revenue each year. The biopharmaceutical company earns $-120,580,000.00 in net income (profit) each year or ($4.01) on an earnings per share basis. Revance Therapeutics employs 134 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is http://www.revance.com.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  495
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel